Journal Article DKFZ-2025-01554

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png
Neoadjuvant immune checkpoint inhibition improves protection against hepatic melanoma metastasis.

 ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;

2025
Elsevier Science Amsterdam [u.a.]

Cancer letters 632, 217950 () [10.1016/j.canlet.2025.217950]
 GO

This record in other databases:

Please use a persistent id in citations: doi:

Abstract: Liver metastasis of cutaneous melanoma (CM) correlates with a decreased response to immune checkpoint inhibition (ICI). Here, we investigated whether neoadjuvant ICI protects against liver metastasis to prevent the development of therapy resistances.A stage II CM was modeled by intracutaneous injections of WT31 or B16F10 luc2 melanoma cells. Combined ICI (anti-PD-1/ anti-CTLA-4) was applied in murine models of hepatic melanoma metastasis comparing neoadjuvant or adjuvant regimens. Immune cell composition and responses in the liver and CMs were comparatively analyzed by scRNA-Seq, flow cytometry, immunofluorescence, in situ hybridization and multiplex cytokine assays.Neoadjuvant ICI resulted in improved protection against liver metastasis in comparison to adjuvant therapy. This superior response was associated with an expansion of T cells in CMs, the peripheral blood and the liver. An increased expression of TH1-associated markers and a downregulation of TH2-associated markers were detected in T cells from CMs and livers of mice by scRNA-Seq and immunofluorescence after neoadjuvant ICI. Analysis of hepatic cytokines also revealed lower levels of TH2-associated IL-4 and of IL-15.Our data demonstrate that neoadjuvant ICI provides superior protection against hepatic melanoma metastasis with a shift towards an anti-tumor TH1 immune response. Therefore, neoadjuvant ICI is a promising therapeutic option for CM to prevent the development of organ-specific therapy resistance mechanisms.

Classification:

Note: #EA:A370# / Volume 632, 1 November 2025, 217950

Contributing Institute(s):
  1. KKE Dermatoonkologie (A370)
  2. KKE Neuroimmunologie und Hirntumorimmunologie (D170)
  3. DKTK HD zentral (HD01)
Research Program(s):
  1. 311 - Zellbiologie und Tumorbiologie (POF4-311) (POF4-311)

Appears in the scientific report 2025
Database coverage:
Medline ; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Life Sciences ; Ebsco Academic Search ; Essential Science Indicators ; IF >= 5 ; JCR ; NationallizenzNationallizenz ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
Click to display QR Code for this record

The record appears in these collections:
Document types > Articles > Journal Article
Institute Collections > D170
Public records
Publications database

 Record created 2025-07-29, last modified 2025-08-29



Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)